Expedientes Secretos X del CELEBREX (celecoxib)  !!!

Data-Medicos 
Dermagic/Express No.7-(X-12) 
11 Noviembre 2.004 /11 November 2.004 

EDITORIAL ESPAÑOL                                                  
=================

El CELEBREX (CELECOXIB) molecula selectiva COX-2 casi hermana del VIOXX (ROFECOXIB), todavia esta en el mercado aun habiendose demostrado cientificamente sus efectos nocivos en amplios estudios a nivel cardiaco, renal, hepatico, piel, sangre y otros mas. En estos expedientes X les traigo 7 perlas NEGRAS mas sobre el CELEBREX..

En un programa televisivo latino (AL ROJO VIVO), se hizo el anuncio publico del PELIGRO de tomar esta pastilla porque aumenta el riesgo de sufrir un evento cardiaco,,,

Y que esperan para sacarla del mercado ???? que se muera un presidente o alto funcionario y sea peor la situacion ???? Recuerden tengo 3 años diciendolo....

Saludos a todos

Dr. Jose Lapenta R


ENGLISH EDITORIAL
================
The CELEBREX (CELECOXIB) selective molecule COX-2 almost sister of the VIOXX (ROFECOXIB), still this in the market even there being demonstrated you scientifically their noxious effects in wide studies at heart, renal, hepatic level, skin, blood and other but. In these files X brings you 7 BLACK pearls  on the CELEBREX..

In a Latin television program ( THE RED one I LIVE), the announcement was made I publish of the DANGER of taking this pill because the risk increases of suffering a heart event,
 

And that they wait to take it out of the market???? that he dies a president or high official and be the situation worse????  Remember I am 3 years saying it....

 

Greetings to all

                                                         HOT LINK

1.) Acute cholestatic hepatitis associated with celecoxib.

Ann Pharmacother. 2002 Dec;36(12):1887-9.
Comment in:
Ann Pharmacother. 2003 May;37(5):748; author reply 748-9.

Grieco A, Miele L, Giorgi A, Civello IM, Gasbarrini G.

Department of Internal Medicine, Catholic University of Sacred Heart, Rome, Italy. [email protected]

OBJECTIVE: To report a case of acute cholestatic hepatitis associated with the selective cyclooxygenase-2 inhibitor celecoxib. CASE SUMMARY: A 41-year-old white man was hospitalized for jaundice after 2 doses of celecoxib 200 mg for pain associated with right-knee trauma. Laboratory workup showed hyperbilirubinemia, mildly elevated serum transaminase concentrations, and cholestasis. Abdominal imaging showed no dilation of the biliary tree. Histology showed cholestasis, with bile plugs in dilated bile canaliculi and a mild portal infiltrate that are highly suggestive of drug-induced cholestasis. DISCUSSION: This is the fourth report in the English-language literature describing cholestatic hepatitis temporally related to celecoxib use, the second supported by histologic findings typical of drug-induced cholestasis, and the first in a patient who denied use of alcoholic beverages and was taking no other drugs or herbal products at the time of the reaction. The Naranjo probability scale indicated that celecoxib was a probable cause of acute cholestatic hepatitis in this patient. CONCLUSIONS: Cholestatic hepatitis is a well-recognized adverse effect of several drugs. Although celecoxib is considered to have a very low potential for hepatic toxicity, well-documented reports of adverse reactions can contribute significantly to the definition of more accurate safety profiles for new drugs introduced into clinical practice.

2.) Toxic epidermal necrolysis after celecoxib therapy.

Pharmacotherapy. 2002 Sep;22(9):1193-5.
Berger P, Dwyer D, Corallo CE.

Department of Dermatology, Box Hill Hospital, Victoria, Australia.

Toxic epidermal necrolysis (TEN) is a rare disease that is defined by extensive detachment of full-thickness epidermis. It most often is related to an adverse drug reaction. The drugs implicated in most cases of TEN have been sulfonamides, anticonvulsants, allopurinol, and some of the conventional nonsteroidal antiinflammatory agents. We describe a patient who developed a generalized desquamating rash after therapy with celecoxib.
 

3.) [Celecoxib induced toxiderma with positive patch-test]

Ann Dermatol Venereol. 2002 Feb;129(2):203-5.

[Article in French]

Verbeiren S, Morant C, Charlanne H, Ajebbar K, Caron J, Modiano P.

Service de Dermatologie, Centre Hospitalier Saint-Philibert, Universite Catholique de Lille, 115, rue du Grand But, BP 249, 59462 Lille.

INTRODUCTION: Celecoxib (Celebrex(R)) is a new generation non-steroidal anti-inflammatory drug, recently introduced in France. We report a maculopapular rash due to this drug with positive patch-tests. CASE REPORT: A forty year-old man received with 3 tablets/day of celecoxib for intercostal pain. Nine days after initiation of treatment a maculopapular rash appeared. At the end of treatment, the eruption persisted for two days, then rapidly improved within one week. Six weeks later, patch-tests with celecoxib diluted at 20 p. 100 in petrolatum were positive at 48 hours. DISCUSSION: Cutaneous reactions due to celecoxib are rare. In our case report, the delay, clinical aspect, improvement on withdrawal of treatment and positive patch test all emphasize the imputability of celecoxib. We wish to underline the possible cutaneous reactions with this new non-steroidal anti-inflammatory drug.

4.) Toxic epidermal necrolysis due to administration of celecoxib (Celebrex).

South Med J. 2002 Oct;95(10):1213-4.

Comment in:
South Med J. 2003 Mar;96(3):320-1.

Friedman B, Orlet HK, Still JM, Law E.

Joseph M. Still Burn Center, Doctor's Hospital, Augusta, GA, USA.

A 41-year-old woman was given celecoxib (Celebrex) for the treatment of carpal tunnel syndrome. An erythematous rash developed that progressed to exfoliative dermatitis, and the patient was diagnosed with toxic epidermal necrolysis. After transfer to the burn unit, she was treated with topical mupirocin calcium cream and bismuth tribromophenatein petrolatum gauze dressings. Her wounds healed well. This is the first case report of toxic epidermal necrolysis due to treatment with celecoxib of which we are aware.




5.) Celecoxib-induced methemoglobinemia.

Celecoxib-induced methemoglobinemia.

Ann Pharmacother. 2004 Oct;38(10):1635-8. Epub 2004 Aug 24

Kaushik P, Zuckerman SJ, Campo NJ, Banda VR, Hayes SD, Kaushik R.

Department of Internal Medicine, Hospital Medicine Group, Baton Rouge General Medical Center, Baton Rouge, LA, USA. [email protected]

OBJECTIVE: To report a case of acute methemoglobinemia in a patient treated with celecoxib for osteoarthritis. CASE SUMMARY: A 72-year-old African American man developed an acute confusional state (ACS) one month after receiving celecoxib for osteoarthritis of his knee joints. There was no other identifiable cause of ACS such as any recognized cause of metabolic encephalopathy, meningoencephalitis, cerebrovascular accident, or drug intoxication. He was found to have severe methemoglobinemia (serum methemoglobin fraction 9%; reference range 0-0.2). His symptoms improved substantially, and serum methemoglobin levels decreased to 0.7% after the initiation of methylene blue therapy. He was discharged on oral riboflavin and ascorbic acid and was advised not to restart celecoxib therapy. He had not shown any recurrence of the symptoms at a follow-up visit 2 months after the withdrawal of celecoxib. DISCUSSION: Celecoxib is a nonsteroidal antiinflammatory drug that selectively inhibits cyclooxygenase-2. Acute methemoglobinemia can present as a syndrome of nonspecific symptoms such as headache, nausea, fatigue, dyspnea, and lethargy; these may progress to respiratory depression, coma, shock, seizures, and death. Although acute methemoglobinemia has been reported with the use of several drugs, including sulfonamides, as of August 13, 2004, this is the first case report of severe methemoglobinemia manifesting as ACS with celecoxib therapy. Use of the Naranjo probability scale indicated a probable relationship between the clinical manifestations of methemoglobinemia and celecoxib therapy in this patient. CONCLUSIONS: Celecoxib can be associated with acute methemoglobinemia. Prompt diagnosis of this condition, withdrawal of celecoxib, and treatment with the antagonists (methylene blue, ascorbic acid, riboflavin) can reverse this potentially serious condition.

 

6.) Anaphylaxis to celecoxib.

Ann Allergy Asthma Immunol. 2001 Jul;87(1):72-3.

Levy MB, Fink JN.

Department of Pediatrics and Medicine, Medical College of Wisconsin, Milwaukee 53201, USA. [email protected]

BACKGROUND: Adverse reactions such as urticaria, angioedema, asthma, and anaphylaxis are known to be associated with nonsteroidal anti-inflammatory agents (NSAIDs). Celecoxib (Pfizer/Searle, Caguas, PR) is a new NSAID that differs in structure and mechanism of action of other similar drugs of this class. OBJECTIVE: Evaluation of a case of anaphylaxis to celecoxib (Celebrex). METHODS AND RESULTS: This report describes a 55-year-old woman who experienced the acute onset of pruritus, urticaria, respiratory distress, and hypotension minutes after ingesting a celecoxib capsule. She had taken the drug a previous time for tendonitis without difficulty. Treatment with epinephrine, corticosteroids, and intravenous fluids was successful. An IgE mechanism could not be detected. She has avoided the drug and has had no further problems. CONCLUSIONS: This is the first patient report of anaphylaxis attributable to celecoxib, a new NSAID. This suggests that physicians and other health care professionals should be aware of the potential serious side effects of this drug.

 

7.) Renal failure associated with the use of celecoxib and rofecoxib.

Drug Saf. 2002;25(7):537-44.

Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J.

Division of Drug Risk Evaluation, Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA. [email protected]

OBJECTIVE: Celecoxib and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (COX-2) isoenzyme at therapeutic concentrations. The nephrotoxic potential of selective COX-2 inhibitors has not been clearly established. This study was conducted in order to understand the association between acute renal failure and the two COX-2 inhibitors celecoxib and rofecoxib. METHODS: A search was performed in the US Food and Drug Administration's (FDA) Adverse Event Reporting System (AERS) to identify cases of renal failure submitted to the FDA. A MEDLINE search of the English language literature was also performed to identify published cases of renal failure associated with celecoxib and rofecoxib. RESULTS: One hundred twenty-two and 142 domestic US cases of celecoxib and rofecoxib-associated renal failure, respectively, were identified in the AERS database. The literature search identified 19 cases of acute renal impairment in association with celecoxib and rofecoxib. In addition, drug regulatory authorities in the UK, Canada, and Australia have received about 50 reports of renal failure with celecoxib and rofecoxib. Descriptive statistics of the AERS cases have been summarised in this report. CONCLUSIONS: Data from AERS and published case reports suggest that use of both these drugs is associated with renal effects similar to that of conventional nonselective NSAIDs. Physicians should be aware that serious or life-threatening renal failure has been reported in patients with normal or impaired renal function after short-term therapy with celecoxib and rofecoxib. Patients at greatest risk for renal injury are those with pre-existing renal impairment, heart failure, liver dysfunction, those taking diuretics and/or ACE inhibitors, and the elderly. Kidney function should be monitored closely for any signs of potential renal injuries soon after initiating treatment with these agents, especially in high-risk populations. In addition, healthcare practitioners should adequately warn patients of the signs and symptoms of serious renal toxicity, and of the need for them to see their physician promptly if they occur. Celecoxib and rofecoxib are not recommended for use in patients with advanced renal disease.

 

=================================================================== 
DATA-MEDICOS/DERMAGIC-EXPRESS No 6-(X-12)  11/11/2.004 DR. JOSE LAPENTA R. 
===================================================================